$clpt Neurona “Receiving PRIME designation from the EMA is a major milestone for Neurona and strong external validation of NRTX-1001’s potential to change the treatment paradigm for people living with drug-resistant focal epilepsy,” said Cory R. Nicholas, Ph.D., Neurona’s Chief

$clpt $qure Sarah Tabrizi speaks out on LinkedIn I am saddened by the shift in position taken by the current FDA administration regarding the regulatory pathway for uniQure’s AMT-130 program. This is disappointing news for Huntington’s disease patients and families -

$CLPT thread

$HZO $MBUU

$DKNG Complete ineptitude at $PENN continues

Added more $CLPT under $17

$DKNG Funny, not one post on here about $300mm customer-favorable hit in Sept/Oct...>100% of guide adjust. (5.2% SB margin in Q vs. 6.7% in 9mos FYtd) Anyone commenting on $DKNG ever cover a casino before?

$CLPT

$DKNG

"Majority of EBITDA guidance reduction was consumer-favorable sports outcomes" Wish some casino analysts followed this stock on Twitter. $DKNG

$CLPT is starting to get cheap here. Need to start looking at ‘26 numbers which is less than 2 months away.

Fintwit is a joke...maybe worse. $DKNG

$CLPT Q3 $8.9M rev masks the pivot: IRRAS acq. unlocks $500M+ neurocritical care TAM, AMT-130 possible reversal, 60+ biopharma partners (9 FDA expedited). 2026 guidance $57M is conservative: robotics, new labs & gene therapy approvals prime a 2026 breakout. Buying the dip! 🚀

THE BROMANCE ENDS IN A DECLARATION OF WAR

Always keep things in perspective. $CLPT $DKNG $ABNB $CCC $MBUU $HZO

Honestly, the only thing I take away from $CLPT call is this "If we take only the FDA-expedited partner products AND only assume 1% penetration of patient populations, it results in $300mm incremental revenues for ClearPoint on an annual basis" 8.0x $360mm Revs = $2.9bn mkt cap

100%

$ABNB

$MKL Share cannibal.

$RIVN